poisar

Stocks · News reference

Coloplast Q3 Adj. EPS $0.10, Inline, Sales $1.144B Beat $1.120B Estimate

Aug 18, 2026, 9:04 AMBenzinga Newsdesk

Coloplast (OTC:CLPBY) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 66.67 percent increase over earnings of $0.06 per share from the same period last year. The

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CLPBY
Source
benzinga
Observed
Aug 18, 2026, 9:04 AM
Checked
Aug 18, 2026, 9:04 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Jun 3, 2026, 1:00 PMNa

    Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men

    Coloplast announced FDA approval of Titan Prime, its next-generation inflatable penile prosthesis (IPP) designed to treat severe erectile dysfunction affecting approximately 30 million men in the US. The device features proprietary Bioflex polymer technology offering greater strength and durability than silicone competitors, with improved comfort and concealability. Titan Prime will be available in the U.S. starting in late 2026 through a phased launch.

    Read original at globenewswire-inc
    CLPBY